Caracteristicile clinice și paraclinice ale infecției cronice cu virusul hepatitic B și răspunsul la terapia antivirală

Mirabela Maximciuc; Ina Bîstrițchi; Irina Russu; Stela Cojocaru; Valentina Poting-Rascov; Natalia Dubineanschi; Pavel Micsansch; Tiberiu Holban; Mariana Avricenco; Andrian Osipov

Clinical and paraclinical features of chronic hepatitis B virus infection and response to antiviral therapy

Authors

Mirabela Maximciuc Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0003-1127-742X
Ina Bistritchi Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0003-3626-5281
Irina Russu Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0002-2759-3171
Stela Cojocaru Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0002-1420-8772
Valentina Poting-Rascov Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0003-2242-8182
Natalia Dubineanschi Nicolae Testemițanu State University of Medicine and Pharmacy
Pavel Micsansch Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0002-1809-0767
Tiberiu Holban Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0003-0923-3129
Mariana Avricenco Republican Clinical Hospital for Infectious Diseases "Toma Ciorba" https://orcid.org/0009-0006-7014-3834
Andrian Osipov Republican Clinical Hospital for Infectious Diseases "Toma Ciorba"

Keywords:

Nucleos(t)idic analogues, HBV, virological response

Abstract

Chronic hepatitis B virus (HBV) infection remains a global public health problem. Antiviral treatment with high barrier resistance nucleos(t)idic analogues is the treatment of choice due to their high antiviral efficacy and safety profile. A retrospective study was conducted based on the analysis of the observation records of 50 treatment-naive and treatmentexperienced patients with chronic HBV infection who received antiviral treatment with AN at the Clinical Hospital of Infectious Diseases „Toma Ciorbă” during 2019-2021. Our study showed high VR rates and a favourable safety profile for naive patients and treatment-experienced patients. Mean age was 49.12±1.59 years, 72% male patients. 88% of patients were with chronic viral hepatitis B. Of the 50 patients studied, 27 patients were treatment naive and 23 patients were treatment experienced. Virusologic response (VR) at 24 months of treatment was achieved in 73.68%, with the highest proportion of patients in group II (88.89%). Treatment with AN showed high VR rates and a favorable safety profile for treatmentnaive and treatment-experienced patients. Antiviral treatment is long-term, which requires patient adherence and careful clinical and paraclinical monitoring, respecting the criteria for discontinuation without affecting the long-term prognosis, such as exacerbation of disease progression.

References

1. Bertoletti A., Kennedy P. T. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol. 2015;12(3):258-263. https://doi.org/10.1038/cmi.2014.79

2. Croagh C. M., Lubel J. S. Natural history of chronic hepatitis B: phases in a complex relationship. World J. Gastroenterol 2014;20(30):10395-10404. https://doi.org/10.3748/wjg.v20.i30.10395

3. Eng-Kiong T., Anna S. F. Lok. Epidemiology, transmission, and prevention of hepatitis B virus infection. https://www.uptodate.com/contents/epidemiology-transmission-and-prevention-of-hepatitis-b-virus-infection/print.

4. European Association For The Study Of The Liver. EASL 2017, Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology. 2017; 67 (2): 370-98.

5. Hyung J., Ji Hoon K., Jun Yong P. et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clinical and Molecular Hepatology 2020;26:411-429. https://doi.org/10.3350/cmh.2020.0049

6. Harshad D., Sumeet K., Juan Pablo Arab et. al. Global burden of liver disease: 2023 update.https://www.journal-of-hepatology.eu/article/S0168-8278(23)00194-0/fulltext.

7. Invernizzi F., Vigano M., Grossi G., Lampertico P. The prognosis and management of inactive HBV carriers. Liver Int. 2016; 36(S1):100-104.

https://doi.org/10.1111/liv.13006

8. Lampertico P., Agarwal K., Berg T. et. al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398.9. https://doi.org/10.1016/j.jhep.2017.03.021

9. Lin C. L., Kao J. H. Prevention of hepatitis B virus-related hepatocellular carcinoma. Hepatoma Res. 2021,7, S303-S309. https://doi.org/10.20517/2394-5079.2020.125

10. Lok A. S., Mcmahon B. J., Brown R. S. et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63(1):284-306. https://doi.org/10.1002/hep.28280

11. Minmin Zhu, Hui W., Tao L. et al. Current treatment of chronic hepatitis B: Clinical aspects and future directions. Front. Microbiol., 08 September 2022 Sec. Virology Volume 13 - 2022 https://doi.org/10.3389/fmicb.2022.975584

12. Ott J. J., Stevens G. A., Groeger J., Wiersma S. T. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012 Mar;30(12):2212-9. Epub 2012 Jan 24. https://doi.org/10.1016/j.vaccine.2011.12.116

13. Raimondo G., Locarnini S., Pollicino T. et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol 2019;71(2):397-408. https://doi.org/10.1016/j.jhep.2019.03.034

14. Supravegherea epidemiologică a hepatitelor virale B, C şi D, măsurile de control și răspuns anul 2022, https://ansp.md/wp-content/uploads/2023/05/Supravegherea-epidemiologica-a-hepatitelor-virale.pdf.

15. Sarin S. K., Kumar M., Lau G. K., Abbas Z., Chen C. J. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10(1):1-98. https://doi.org/10.1007/s12072-015-9675-4

16. Terrault N. A., Lok A. S., Mcmahon B. J., Chang K. M. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018;67(4):1560-1599. https://doi.org/10.1002/hep.29800

17. World Health Organization. Hepatitis B Fact Sheet; Published Online 12 July 2023. Available online:https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (accessed on 5.08. 2023).

18. Young-Suk L., Woong R., Douglas D. et. al. Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B. Viruses 2023, 15(4), 997; https://doi.org/10.3390/v15040997

Downloads

PDF (Romanian)

Published

2026-04-15

Issue

No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a

Section

Articles

License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite

[1]

Maximciuc, M. et al. 2026. Clinical and paraclinical features of chronic hepatitis B virus infection and response to antiviral therapy. Public Health Economy and Management in Medicine. 3(96) (Apr. 2026), 60–66.

Download Citation

Most read articles by the same author(s)

Irina Russu, Mariana Avricenco, Ina Bistritchi, Nina Tamojnic-Mazureac, Adelina Butnaru, Tiberiu Holban, The evolution of liver fibrosis in patients with viral hepatitis C after treatment with direct-acting antiviral drugs , Public Health Economy and Management in Medicine: No. 2(104) (2025): Supliment. Al VI-lea Congres Național de Gastroenterologie și Hepatologie din Republica Moldova cu participare internațională
Gheorghe Ivanov, Irina Russu, Reconstructive anterior segment surgery , Public Health Economy and Management in Medicine: No. 1(92) (2022): Supliment. Conferința științifico-practică a Oftalmologilor din municipiul Chișinău cu participare națională și internațională, ediția a VII-a „Actualități în oftalmologie”
Nina Tamojnic-Mazureac, Tiberiu Holban, Irina Russu, Ina Bistritchi, Valentina Poting-Rascov, Elena Golovco, Victoria Bulgac, Antiviral treatment of viral hepatitis C in patients with HIV infection , Public Health Economy and Management in Medicine: No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a
Gheorghe Ivanov, Irina Russu, Refractive lens exchange , Public Health Economy and Management in Medicine: No. 1(92) (2022): Supliment. Conferința științifico-practică a Oftalmologilor din municipiul Chișinău cu participare națională și internațională, ediția a VII-a „Actualități în oftalmologie”
Mariana Avricenco, Irina Russu, Tiberiu Holban, Influence of direct acting antivirals with/without ribavirin on hematological parameters in cirrhosis with HCV , Public Health Economy and Management in Medicine: No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a
Pavel Micsanschi, Ina Bistritchi, Irina Russu, Stela Cojocaru, Mirabela Maximciuc, Iurie Climasevschi, Tiberiu Holban, Angela Nagit, The dynamics of clinical and paraclinical indices under the action of first-line antiretroviral regimes in the Republic of Moldova , Public Health Economy and Management in Medicine: No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a
Liviu Iarovoi, Angela Nagit, Nicoleta Minzatean, Pavel Micsanschi, Lilia Cojuhari, Lilia Baba, Vasile Lazar, Tiberiu Holban, Cryptococcal meningitis in patients with HIV/AIDS , Public Health Economy and Management in Medicine: No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a
Irina Russu, Tiberiu Holban, Mariana Avricenco, Mirabela Maximciuc, Ina Bîstrițchi, Stela Cojocaru, Nina Tamojnic-Mazureac, Valentina Poting-Rascov, Pavel Micsanschi, Natalia Dubineanschi, Natalia Culiuc, Andrian Osipov, Efficacy of antiviral treatment with Velpatasvir + Sofosbuvir and Glecaprevir + Pibrentasvir in patients with chronic VHC , Public Health Economy and Management in Medicine: No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a
Tiberiu Holban, Cuvânt inainte , Public Health Economy and Management in Medicine: No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a

Clinical and paraclinical features of chronic hepatitis B virus infection and response to antiviral therapy

Authors

Keywords:

Abstract

References

Downloads

Published

Issue

Section

License

How to Cite

Most read articles by the same author(s)

Similar Articles

Language

issn

oa cc-by-nc-sa

road-issn

crossref member

ibn